NCT07215468进行中（未招募）2 期
A Phase 2b Study of the Safety, Pharmacokinetics, and Efficacy of the Combination of TMB-365 and TMB-380 as Maintenance Therapy in HIV-1 Infected Individuals Suppressed With Combination Antiretroviral Therapy
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 88
- 试验地点
- 16
- 主要终点
- Antiviral activity of TMB-365 and TMB-380 as maintenance therapy compared to daily oral cART
研究概览
简要总结
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test the combination of the antibodies as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 48 weeks.
Researchers will compare TMB-365/TMB-380 given IV every 8 weeks to continuation of daily oral cART to see if TMB-365/TMB-380 can also maintain viral suppression.
Participants will:
- Receive TMB-365/TMB-380 infusion or take oral cART as scheduled for 48 weeks
- Visit the clinic as schedule for checkups and tests
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age on the day of Screening.
- •Asymptomatic HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by Geenius™ or a second antibody test by a method other than the initial rapid HIV and/or E/CIA test, or by HIV-1 antigen, plasma HIV-1 RNA viral load at or prior to screening.
- •On continuous suppressive cART for at least 6 months prior to Screening with one documented HIV-1 RNA level <50 copies/mL within 6 months of Screening. Continuous cART is defined as no interruptions greater than 3 consecutive days. cART is defined as a DHHS recommended regimen. Study participants should be on a stable oral regimen for at least 3 months prior to Screening.
- •Screening plasma HIV-1 RNA < 50 copies/mL
- •CD4+ T cell count >350 cells/mm3
- •Laboratory values obtained within 35 days prior to the first dose:
- •Hemoglobin ≥ 10.0 g/dL
- •Platelet count ≥ 100,000/mm3
- •Absolute neutrophil count ≥ 1,000/mm3
- •Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x upper limit of normal (ULN)
- •Creatinine clearance (CrCl) of ≥ 50 mL/min
- •Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
- •In the opinion of the principal investigator or designee, has understood the information provided; written informed consent needs to be given before any study-related procedures are performed.
- •Persons of childbearing potential sexually active with a partner who can impregnate them, must agree to use one effective method of contraception from the time of signing the consent to completion of the study, and agree to pregnancy testing as per the Schedule of Events and Procedures. Persons of childbearing potential are participants born female who are not surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo-oophorectomy), are not postmenopausal (at least one year without menses), and are not otherwise sterile by medical evaluation.
排除标准
- •History of receipt of any monoclonal antibody for any treatment, including bNAbs, whether naturally occurring, such as VRC01, or modified, such as VRC07-523LS.
- •History of receipt of any long-acting ARV for treatment or prevention of HIV (investigational and commercial), including but not limited to cabotegravir/rilpivirine combination, lenacapavir, and islatravir.
- •Pregnant, planning a pregnancy during the trial period, or lactating.
- •Known allergy/sensitivity or any hypersensitivity to components of the study drug or its formulation, or known allergy to a MAb.
- •History of severe allergic reactions to medications, vaccinations, or monoclonal antibody therapy for other conditions such as COVID.
- •Major psychiatric illness including any history of schizophrenia or severe psychosis, uncontrolled bipolar disorder requiring acute therapy, or suicide attempt in the previous three years.
- •Serious illness requiring systemic treatment and/or hospitalization within 21 days prior to Baseline.
- •Receipt of immunomodulatory agents (e.g., interleukins, interferons, cyclosporine, high dose systemic corticosteroids), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 180 days prior to Baseline.
- •Any chronic or acute medical condition, including chronic Hepatitis B infection, chronic Hepatitis C infection with viremia, drug use and alcohol abuse, which in the opinion of the investigator would interfere with evaluation of the study drug.
- •Lack of adequate venous access.
- •Individuals who have experienced virologic failure during treatment with two or more cART treatment regimens and those being treated with regimens containing either ibalizumab, enfuvirtide, maraviroc, or fostemsavir. Note that a change in treatment regimen for intolerance does not meet criteria for treatment failure.
研究组 & 干预措施
Combination of TMB-365 and TMB-380 antibodies via IV infusions
Experimental
Participants will receive an IV infusion of the combination of TMB-365 and TMB-380 each every 8 weeks.
干预措施: TMB-365 (Drug)
Baseline oral cART
Active Comparator
Participants will continue suppressive daily oral cART
干预措施: Baseline ART (Drug)
Combination of TMB-365 and TMB-380 antibodies via IV infusions
Experimental
Participants will receive an IV infusion of the combination of TMB-365 and TMB-380 each every 8 weeks.
干预措施: TMB-380 (Drug)
结局指标
主要结局
Antiviral activity of TMB-365 and TMB-380 as maintenance therapy compared to daily oral cART
时间窗: Week 48
% of subjects with plasma HIV-1 RNA greater than or equal to 50 c/mL at week 48 by snapshot analysis as defined by US FDA
次要结局
- Number of participants who experience protocol-defined virologic failure(48 weeks)
- Pharmacokinetic profile of TMB-365(Week 48)
- Pharmacokinetic profile of TMB-380(Week 48)
- Safety of maintenance treatment regimen(48 weeks)
- Immune effects of maintenance therapy(48 weeks)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
1 期
TMB-365 and TMB-380 in Suppressed HIV-1 Infected IndividualsHIV-1-infectionNCT05275998TaiMed Biologics Inc.51
招募中
1 期
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid TumorsSelect Advanced Solid TumorsNCT06402201CDR-Life AG42
招募中
1 期
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsAdvanced Solid TumorsNCT05941507LigaChem Biosciences, Inc.300
已完成
1 期
A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male VolunteersHealthyNCT00612196ThromboGenics56
进行中（未招募）
1 期
BG-C9074 单药治疗及其与替雷利珠单抗联合用药治疗晚期实体瘤患者的 1a/1b 期首次人体研究CTR20242829100